Neurocrine
Neurocrine Biosciences, Inc. (NBIX) is a biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for neurological and endocrine diseases. Founded in 1992 and headquartered in San Diego, California, Neurocrine operates in the biopharmaceutical sector, with a focus on conditions such as movement disorders, psychiatric disorders, and endocrine diseases. The company’s core products include Ingrezza (valbenazine), which is approved for the treatment of tardive dyskinesia, and Ongentys (opicapone), used in Parkinson's disease management.